Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia-Pacific Region: A Phase 3 Randomized Controlled Trial.
- DOI
- 10.1097/fjc.0000000000000445
- Published
- 2017 Feb
- Container
- Journal of cardiovascular pharmacology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1097/fjc.0000000000000445,
title = {Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia-Pacific Region: A Phase 3 Randomized Controlled Trial.},
author = {Beatch GN and Bhirangi K and Juul-Moller S and Rustige J},
year = {2017},
journal = {Journal of cardiovascular pharmacology},
doi = {10.1097/fjc.0000000000000445},
url = {https://doi.org/10.1097/fjc.0000000000000445}
}RIS
TY - JOUR TI - Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia-Pacific Region: A Phase 3 Randomized Controlled Trial. AU - Beatch GN AU - Bhirangi K AU - Juul-Moller S AU - Rustige J PY - 2017 JO - Journal of cardiovascular pharmacology DO - 10.1097/fjc.0000000000000445 UR - https://doi.org/10.1097/fjc.0000000000000445 ER -
APA
GN, B., K, B., S, J., & J, R. (2017). Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia-Pacific Region: A Phase 3 Randomized Controlled Trial.. Journal of cardiovascular pharmacology. https://doi.org/10.1097/fjc.0000000000000445
Source records
- pubmed · retrieved 2026-09-26T11:49:51.011Z
- europe-pmc · retrieved 2026-09-26T11:49:51.008Z